{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:34:57Z","timestamp":1753893297020,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"DOI":"10.3389\/fvets.2020.00062","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:04:57Z","timestamp":1581555897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB\/c Mice"],"prefix":"10.3389","volume":"7","author":[{"given":"Yuetao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","article-title":"Rift valley fever: an emerging mosquito-borne disease","volume":"61","author":"Linthicum","year":"2016","journal-title":"Ann Rev Entomol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.antiviral.2016.07.005","article-title":"Rift valley fever virus: unanswered questions","volume":"132","author":"Bird","year":"2016","journal-title":"Antivir Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","article-title":"Rift valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe","volume":"33","author":"Mansfield","year":"2015","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/aid.2005.21.714","article-title":"A survey of vaccines produced for OIE list A diseases in OIE member countries","volume":"114","author":"Roth","year":"2003","journal-title":"Dev Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.3390\/vaccines5030029","article-title":"Current status of rift valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","article-title":"Molecular biology and genetic diversity of rift valley fever virus","volume":"95","author":"Ikegami","year":"2012","journal-title":"Antivir Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27719","DOI":"10.1038\/srep27719","article-title":"A recombinant rift valley fever virus glycoprotein subunit vaccine confers full protection against rift valley fever challenge in sheep","volume":"6","author":"Faburay","year":"2016","journal-title":"Scienti Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-4939-7808-3_8","article-title":"Production and application of insect virus-based VLPs","volume":"1776","author":"Gopal","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4238\/gmr.15017772","article-title":"Development and characterization of rift valley fever virus-like particles","volume":"15","author":"Li","year":"2016","journal-title":"Gene Mol Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.intimp.2018.09.002","article-title":"Equine immunoglobulin F(ab')2 fragments protect mice from rift valley fever virus infection","volume":"64","author":"Zhao","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nature02263","article-title":"Protein degradation and protection against misfolded or damaged proteins","volume":"426","author":"Goldberg","year":"2003","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e18070","DOI":"10.1371\/journal.pone.0018070","article-title":"Efficient cellular release of rift valley fever virus requires genomic RNA","volume":"6","author":"Piper","year":"2011","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4142\/jvs.2018.19.2.200","article-title":"Packaging of rift valley fever virus pseudoviruses and establishment of a neutralization assay method","volume":"19","author":"Li","year":"2018","journal-title":"J Veterin Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/00480169.2012.738403","article-title":"Schmallenberg virus, a novel orthobunyavirus infection in ruminants in Europe: potential global impact and preventive measures","volume":"61","author":"Conraths","year":"2013","journal-title":"N Z Veterin J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"New Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1007\/s00253-018-9361-2","article-title":"Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses","volume":"102","author":"Li","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/eji.1830261109","article-title":"Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes","volume":"26","author":"Bachmann","year":"1996","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cimid.2013.02.002","article-title":"Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design","volume":"36","author":"Liu","year":"2013","journal-title":"Compar Immunol Microbiol Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00262-010-0895-0","article-title":"Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles","volume":"59","author":"Pejawar-Gaddy","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11152","DOI":"10.1128\/JVI.78.20.11152-11160.2004","article-title":"Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88","volume":"78","author":"Yang","year":"2004","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.virol.2004.05.025","article-title":"Ebola and marburg virus-like particles activate human myeloid dendritic cells","volume":"326","author":"Bosio","year":"2004","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1016\/j.vaccine.2014.05.064","article-title":"Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in hecolin(R)","volume":"32","author":"Zhang","year":"2014","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Exp Rev Vacc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1128\/JVI.00841-11","article-title":"Creation of a nonspreading rift valley fever virus","volume":"85","author":"Kortekaas","year":"2011","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.virol.2008.12.011","article-title":"Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses","volume":"385","author":"Habjan","year":"2009","journal-title":"Virology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"de Boer","year":"2010","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of rift valley fever virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fvets.2020.00062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:04:59Z","timestamp":1581555899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fvets.2020.00062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":29,"alternative-id":["10.3389\/fvets.2020.00062"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2020.00062","relation":{},"ISSN":["2297-1769"],"issn-type":[{"type":"electronic","value":"2297-1769"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"article-number":"62"}}